Bipolar Disorders Treatment Market Research Report Information by Drug Type (Mood Stabilizer, Anticonvulsant, Antipsychotic Drug, and Antidepressant Drug), Mechanism of Action (Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitor, Monoamine Oxidase Inhibitors, Beta Blockers, and Tricyclic Antidepressant Drug), End User (Hospitals and Clinics, Multispecialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)— Forecast till 2032.

Bipolar Disorders Treatment Market Scenario

The bipolar disorders treatment market is anticipated to reach USD 5.8 Billion by 2032 at 3.4% CAGR during the forecast period 2023-2032. Bipolar disorder is a manic-depressive disorder, which is a type of mental illness. It is characterized by mood swings and mood episodes appear during the illness. Manic and depressive episodes are common mood episodes observed in bipolar disorders. The government initiatives for treatment of bipolar disorders, advancement in combination drugs, and growing demand for antidepressant drugs are expected to drive the growth of the market. Moreover, growing research and development activities conducted by government and nonprofit organizations are contributing to the growth of the market. For instance, Harvard University started Harvard brain science initiative (HBI) for R&D on bipolar disorders. This program has provided USD 3 million in funds to the research and development related to bipolar disorders. The side effects associated with therapy, low diagnosis rate, and dearth of experts may hamper the growth of the global market during the assessment period.  

Bipolar Disorders Treatment Market Segmentation

The global bipolar disorders and treatment market has been segmented on the basis of drug class, mechanism of action, and end user. Based on drug type, the global market has been classified into mood stabilizer, antipsychotic drugs, antianxiety drugs, antidepressant drugs, anticonvulsants, and others. Based on the mechanism of action, the global market has been segmented into selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, monoamine oxidase inhibitors, beta-blockers, tricyclic antidepressant drug, and others. The global market, by end user, has been segmented into hospitals and clinics, multispecialty centers, and others. The bipolar disorders treatment market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European market has been bifurcated into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bipolar disorders treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.  Key PlayersAllergan (Ireland), AstraZeneca (UK), Eli Lilly and Company(US), GlaxoSmithKline(UK), Abbott (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer Inc. (US), Cephalon Inc. (US), Otsuka America Pharmaceutical Inc. (US), and Gedeon Richter plc (Hungary) are some of the key players operating in the bipolar disorders treatment market.   

Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are likely to dominate the global bipolar disorders and treatment market owing to technological advancement, presence of major players in the region, well-established healthcare system, and increasing cases of bipolar disorders in the region. According to the National Institute of Mental Health (NIMH), approximately 3% of adults in the US were suffering from bipolar disorders in 2016 and this percentage is expected to increase significantly in the future due to changing lifestyles.  The European market is expected to be the second-largest bipolar disorders and treatment market. The market growth in this region can be attributed to the increasing number of mental disorders, increasing government funding for treatment of bipolar disorders, and growing research and development activities related to mental health. For instance, in November 2017, Mental Health UK launched a partnership with Lloyds Banking Group to help bipolar disorder patients and to manage and improve their financial and mental health. Asia-Pacific is expected to be the fastest-growing bipolar disorders and treatment market during the forecast period owing to the increasing prevalence of genetic disorders, growing awareness about bipolar disorders, and rising investment by major players in the region. According to the Black Dog Institute, bipolar disorder is related with the genetic condition of an individual, if the parents are suffering from bipolar disorder it is more than 10% likely that their children will experience the same condition in future. The Middle East & Africa is expected to account for the smallest share of the bipolar disorders treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Bipolar disorders treatment market Segmentation

Bipolar disorders treatment Drug Type Outlook

• Mood Stabilizer


• Antipsychotic Drugs


• Antianxiety Drugs


• Antidepressant drugs


• Anticonvulsants


• Others

Bipolar disorders treatment Mechanism of Action Outlook

• Selective Serotonin Reuptake Inhibitor


• Serotonin Norepinephrine Reuptake Inhibitor


• Monoamine Oxidase Inhibitors


• Beta-Blockers


• Tricyclic Antidepressant Drug


• Others

Bipolar disorders treatment End User Outlook

• Hospitals and Clinics


• Multispecialty Centres


• Others

Bipolar disorders treatment Region Outlook

• Americas




• North America


• US


• Canada


• Latin America

• Europe




• Western Europe


• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe


• Eastern Europe




• Asia-Pacific




• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific

• Middle East & Africa




• Middle East


• Africa

Bipolar disorders treatment Key Players Outlook

• Allergan


• AstraZeneca


• Eli Lilly and Company


• GlaxoSmithKline


• Abbott


• Bristol-Myers Squibb


• Johnson & Johnson


• Pfizer Inc.


• Cephalon Inc.


• Otsuka America Pharmaceutical Inc.


• Gedeon Richter plc


• Others

Intended Audience

• Bipolar disorders and treatment centers


• Contract research organizations (CROs)


• Research and development (R&D) companies


• Government research laboratories


• Independent research laboratories


• Government and independent regulatory authorities


• Market research and consulting service providers


• Medical research laboratories


• Academic medical institutes and universities

Report Attribute/Metric	Details
Market Size	2032 :USD 5.8 Billion
CAGR	3.4% (2023–2032)
Base Year	2021
Forecast Period	2023-2032
Historical Data	2020
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Drug Type, Mechanism of Action and End User
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Allergan (Ireland), AstraZeneca (UK), Eli Lilly and Company(US), GlaxoSmithKline(UK), Abbott (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer Inc. (US), Cephalon Inc. (US), Otsuka America Pharmaceutical Inc. (US), and Gedeon Richter plc (Hungary)
Key Market Opportunities	side effects associated with therapy, low diagnosis rate, and dearth of experts
Key Market Drivers	·  government initiatives for treatment of bipolar disorders ·  advancement in combination drugs ·  growing demand for antidepressant drugs